Cure My Disease

Don't miss your cure!

 Log in / Sign up

Monthly HIV prevention pill trial halted Mid-Study

NCT ID NCT04652700

Terminated Prevention Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a once-monthly pill called islatravir to prevent HIV infection in cisgender men and transgender women who have sex with men and are at high risk. About 494 participants were enrolled, but the trial was terminated early. The main goal was to check safety and see if the pill could prevent HIV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV PREEXPOSURE PROPHYLAXIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PREEXPOSURE PROPHYLAXIS

Contacts and locations

Locations

  • Bridge HIV - San Francisco Department of Public Health ( Site 0003)

    San Francisco, California, 94102, United States

  • Center Hospital of the National Center for Global Health and Medicine ( Site 0101)

    Shinjyuku-ku, Tokyo, 162-8655, Japan

  • Central Texas Clinical Research ( Site 0002)

    Austin, Texas, 78705, United States

  • Centro de Referência e Treinamento DST/AIDS ( Site 0351)

    São Paulo, 04121-000, Brazil

  • Chulalongkorn University-Pediatrics ( Site 0051)

    Bangkok, Bangkok, 10330, Thailand

  • Desmond Tutu HIV Foundation ( Site 0202)

    Cape Town, Western Cape, 7925, South Africa

  • Global Research Institute ( Site 0031)

    Los Angeles, California, 90036, United States

  • HIV Netherlands Australia Thailand Research Collaboration ( Site 0056)

    Bangkok, Bangkok, 10330, Thailand

  • Howard Brown Health Center ( Site 0004)

    Chicago, Illinois, 60613, United States

  • Hôpital Saint-Louis-Infectious Diseases and tropical diseases ( Site 0151)

    Paris, Île-de-France Region, 75010, France

  • Midway Immunology and Research Center ( Site 0014)

    Ft. Pierce, Florida, 34982, United States

  • Orlando Immunology Center ( Site 0010)

    Orlando, Florida, 32803, United States

  • Perinatal HIV Research Unit (PHRU)-HIV Prevention CRS ( Site 0203)

    Johannesburg, Gauteng, 1864, South Africa

  • Ponce De Leon Center Grady Health ( Site 0032)

    Atlanta, Georgia, 30308, United States

  • Research Institute for Health Sciences-Research Institute for Health Sciences Building 1 ( Site 0052

    Chiang Mai, 50200, Thailand

  • Rutgers New Jersey Medical School-Clinical Research Center ( Site 0017)

    Newark, New Jersey, 07103, United States

  • The Crofoot Research Center ( Site 0025)

    Houston, Texas, 77098, United States

  • The GW Medical Faculty Associates-Medicine ( Site 0033)

    Washington D.C., District of Columbia, 20037, United States

  • The University of Mississippi Medical Center ( Site 0012)

    Jackson, Mississippi, 39216, United States

  • The University of North Carolina at Chapel Hill ( Site 0019)

    Chapel Hill, North Carolina, 27599, United States

  • UCLA Center for Clinical AIDS Research and Education ( Site 0011)

    Los Angeles, California, 90035, United States

  • University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 0007)

    Birmingham, Alabama, 35222, United States

  • University of Miami Miller School of Medicine-Infectious Disease ( Site 0029)

    Miami, Florida, 33136, United States

  • Via Libre ( Site 0404)

    Lima, 15001, Peru

  • Wits Reproductive Health and HIV Institute (WRHI)-Research Center ( Site 0201)

    Johannesburg, Gauteng, 2000, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.